Loading...
XNAS
ETON
Market cap436mUSD
Dec 05, Last price  
16.26USD
1D
-3.27%
1Q
-7.98%
IPO
171.00%
Name

Eton Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ETON chart
P/E
P/S
11.18
EPS
Div Yield, %
Shrs. gr., 5y
7.83%
Rev. gr., 5y
109.83%
Revenues
39m
+23.29%
00959,00039,00021,832,00021,251,00031,642,00039,011,000
Net income
-4m
L+308.44%
-7,156,000-12,740,000-18,039,000-28,829,000-2,961,000-9,782,000-936,000-3,823,000
CFO
969k
-85.78%
-4,718,000-8,145,000-18,026,000-22,346,000-4,721,0004,821,0006,815,000969,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
IPO date
Nov 09, 2018
Employees
28
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT